1. LiacourasCA, FurutaGT, HiranoI, et al.Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol2011;128:3, quiz 21. CrossRef

2. FoxVL, NurkoS, FurutaGT. Eosinophilic esophagitis: it's not just kid's stuff. Gastrointest Endosc2002;56:260. CrossRef

3. RothenbergME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol2004;113:11. CrossRef

4. GuajardoJR, PlotnickLM, FendeJM, et al.Eosinophil‐associated gastrointestinal disorders: a world‐wide‐web based registry. J Pediatr2002;141:576. CrossRef

5. NoelRJ, PutnamPE, RothenbergME. Eosinophilic esophagitis. N Engl J Med2004;351:940. CrossRef

6. BlanchardC, WangN, StringerKF, et al.Eotaxin‐3 and a uniquely conserved gene‐expression profile in eosinophilic esophagitis. J Clin Invest2006;116:536. CrossRef

7. SpergelJM, BeausoleilJL, MascarenhasM, et al.The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol2002;109:363. CrossRef

8. KellyKJ, LazenbyAJ, RowePC, et al.Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid‐based formula. Gastroenterology1995;109:1503. CrossRef

9. WalshSV, AntonioliDA, GoldmanH, et al.Allergic esophagitis in children: a clinicopathological entity. Am J Surg Pathol1999;23:390. CrossRef

10. SampsonHA. Food allergy. Part 2: diagnosis and management. J Allergy Clin Immunol1999;103:981. CrossRef

11. SampsonHA. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol1999;103:717. CrossRef

12. BischoffS, CroweSE. Gastrointestinal food allergy: new insights into pathophysiology and clinical perspectives. Gastroenterology2005;128:1089. CrossRef

13. LuTX, SherrillJD, WenT, et al.MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol2012;129:1064. CrossRef

14. CroeseJ, FairleySK, MassonJW, et al.Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc2003;58:516. CrossRef

15. CuryEK, SchraibmanV, FaintuchS. Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children – discussion on daily practice. J Pediatr Surg2004;39:e4. CrossRef

16. AttwoodSE, SmyrkTC, DemeesterTR, et al.Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci1993;38:109. CrossRef

17. CantuP, VelioP, PradaA, et al. Ringed oesophagus and idiopathic eosinophilic oesophagitis in adults: an association in two cases. Dig Liver Dis2005;37:129. CrossRef

18. ShitritAB, ReinusC, ZeidesS, et al.Eosinophilic esophagitis. Isr Med Assoc J2006;8:587.

19. FujiwaraH, MoritaA, KobayashiH, et al.Infiltrating eosinophils and eotaxin: their association with idiopathic eosinophilic esophagitis. Ann Allergy Asthma Immunol2002;89:429. CrossRef

20. MunitizV, Martinez de HaroLF, OrtizA, et al.Primary eosinophilic esophagitis. Dis Esophagus2003;16:165. CrossRef

21. StraumannA, SimonHU. The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy2004;59:15. CrossRef

22. LiacourasCA, WennerWJ, BrownK, et al.Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr1998;26:380. CrossRef

23. FurutaGT. Eosinophils in the esophagus: acid is not the only cause. J Pediatr Gastroenterol Nutr1998;26:468. CrossRef

24. BlanchardC, WangN, RothenbergME. Eosinophilic esophagitis: pathogenesis, genetics, and therapy. J Allergy Clin Immunol2006;118:1054. CrossRef

25. FurutaGT, LiacourasCA, CollinsMH, et al.Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology2007;133:1342. CrossRef

26. FranciosiJP, FiorinoK, RuchelliE, et al. Changing indications for upper endoscopy in children during a 20‐year period. J Pediatr Gastroenterol Nutr2010;51:443. CrossRef

27. DeBrosseCW, CollinsMH, Buckmeier ButzBK, et al.Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982–1999. J Allergy Clin Immunol2010;126:112. CrossRef

28. SpergelJM, Brown‐WhitehornTF, BeausoleilJL, et al.14 years of eosinophilic esophagitis: clinical features and prognosis. J Pediatr Gastroenterol Nutr2009;48:30. CrossRef

29. VeerappanGR, PerryJL, DuncanTJ, et al.Prevalence of eosinophilic esophagitis in an adult population undergoing upper endoscopy: a prospective study. Clin Gastroenterol Hepatol2009;7:420, 426 e1. CrossRef

30. AcevesSS, NewburyRO, DohilMA, et al.A symptom scoring tool for identifying pediatric patients with eosinophilic esophagitis and correlating symptoms with inflammation. Ann Allergy Asthma Immunol2009;103:401. CrossRef

31. YuC, CantorAB, YangH, et al.Targeted deletion of a high‐affinity GATA‐binding site in the GATA‐1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med2002;195:1387. CrossRef

32. RothenbergME. Eosinophilia. N Engl J Med1998;338:1592. CrossRef

33. GleichGJ, FrigasE, LoegeringDA, et al.Cytotoxic properties of the eosinophil major basic protein. J Immunol1979;123:2925.

34. GleichGJ, AdolphsonCR. The eosinophilic leukocyte: structure and function. Adv Immunol1986;39:177. CrossRef

35. KonikoffMR, BlanchardC, KirbyC, et al.Potential of blood eosinophils, eosinophil‐derived neurotoxin, and eotaxin‐3 as biomarkers of eosinophilic esophagitis. Clin Gastroenterol Hepatol2006;4:1328. CrossRef

36. YousefiS, GoldJA, AndinaN, et al.Catapult‐like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med2008;14:949. CrossRef

37. OyaizuN, UemuraY, IzumiH, et al.Eosinophilic gastroenteritis: immunohistochemical evidence for IgE mast cell‐mediated allergy. Acta Pathol Jpn1985;35:759.

38. BischoffSC. Mucosal allergy: role of mast cells and eosinophil granulocytes in the gut. Baillieres Clin Gastroenterol1996;10:443. CrossRef

39. CaldwellJH, SharmaHM, HurtubisePE, et al.Eosinophil gastroenteritis in extreme allergy: Immunopathological comparison with nonallergic gastrointestinal disease. Gastroenterology1979;77:560.

40. CaldwellJH, TennerbaumJI, BronsteinHA. Serum IgE to eosinophilic gastroenteritis. N Engl J Med1975;292:1388. CrossRef

41. CelloJP. Eosinophil gastroenteritis: a complex disease entity. Am J Med1979;67:1097. CrossRef

42. ScudamoreHH, PhillipsSF, SwedlundHA, et al.Food allergy manifested by eosinophilia, elevated immunoglobulin E level, and protein‐losing enteropathy: the syndrome of allergic gastroenteropathy. J Allergy Clin Immunol1982;70:129. CrossRef

43. FurutaGT, AckermanSJ, WershilBK. The role of the eosinophil in gastrointestinal diseases. Curr Opin Gastroenterol1995;11:541. CrossRef

44. IaconoG, CarroccioA, CavataioF, et al.Gastroesophageal reflux and cows milk allergy in infants: a prospective study. J Allergy Clin Immunol1996;97:822. CrossRef

45. SampsonHA. Food Allergy. JAMA1997;278:1888. CrossRef

46. GonsalvesN, YangGY, DoerflerB, et al.Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology2012;142:1451. CrossRef

47. MishraA, WeaverTE, BeckDC, et al.Interleukin‐5‐mediated allergic airways inflammation inhibits surfactant protein C promoter in transgenic mice. J Biol Chem2001;276:8453. CrossRef

48. MishraA, RothenbergME. Intratracheal IL‐13 induces eosinophilic esophagitis by an IL‐5, eotaxin‐1, and STAT6‐dependent mechanism. Gastroenterology2003;125:1419. CrossRef

49. ZuoL, FulkersonPC, FinkelmanFD, et al.IL‐13 induces esophageal remodeling and gene expression by an eosinophil‐independent, IL‐13R alpha2‐inhibited pathway. J Immunol2010;185:660. CrossRef

50. OnbasiK, SinAZ, DoganavsargilB, et al.Eosinophil infiltration of the oesophageal mucosa in patients with pollen allergy during the season. Clin Exp Allergy2005;35:1423. CrossRef

51. AcevesSS, ChenD, NewburyRO, et al.Mast cells infiltrate the esophageal smooth muscle in patients with eosinophilic esophagitis, express TGF‐beta1, and increase esophageal smooth muscle contraction. J Allergy Clin Immunol2010;126:1198. CrossRef

52. Garcia‐ZepedaEA, RothenbergME, OwnbeyRT, et al.Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med1996;2:449. CrossRef

53. FurutaGT, ShermanP. Eotaxin and eosinophilic homing to the gut. J Pediatr Gastroenterol Nutr2000;30:229.

54. BlanchardC, StuckeEM, Rodriguez‐JimenezB, et al.A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol2011;127:208, 217.e1. CrossRef

55. RothenbergME, SpergelJM, SherrillJD, et al.Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet2010;42:289. CrossRef

56. SherrillJD, GaoPS, StuckeEM, et al.Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J Allergy Clin Immunol2010;126:160. CrossRef

57. AboniaJP, RothenbergME. Eosinophilic esophagitis: rapidly advancing insights. Annu Rev Med2012;63:421. CrossRef

58. CollinsMH, BlanchardC, AboniaJP, et al.Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol2008;6:621. CrossRef

59. RothenbergME, MishraA, CollinsMH, et al.Pathogenesis and clinical features of eosinophilic esophagitis. J Allergy Clin Immunol2001;108:891. CrossRef

60. SpergelJM, RothenbergME, CollinsMH, et al.Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double‐blind, randomized, placebo‐controlled trial. J Allergy Clin Immunol2012;129:456, 463 e1‐3. CrossRef

61. AcevesSS, NewburyRO, DohilR, et al.Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol2007;119:206. CrossRef

62. PrasadGA, TalleyNJ, RomeroY, et al.Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol2007;102:2627. CrossRef

63. DesaiTK, StecevicV, ChangCH, et al.Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc2005;61:795. CrossRef

64. SpergelJM, AndrewsT, Brown‐WhitehornTF, et al.Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests. Ann Allergy Asthma Immunol2005;95:336. CrossRef

65. PashaSF, DiBaiseJK, KimHJ, et al.Patient characteristics, clinical, endoscopic, and histologic findings in adult eosinophilic esophagitis: a case series and systematic review of the medical literature. Dis Esophagus2007;20:311. CrossRef

66. RuchelliE, WennerW, VoytekT, et al.Severity of esophageal eosinophilia predicts response to conventional gastroesophageal reflux therapy. Pediatr Dev Pathol1999;2:15. CrossRef

67. KirschR, BokharyR, MarconMA, et al.Activated mucosal mast cells differentiate eosinophilic (allergic) esophagitis from gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr2007;44:20. CrossRef

68. ProtheroeC, WoodruffSA, de PetrisG, et al.A novel histological scoring system to evaluate mucosal biopsies from patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol2009;7:749. CrossRef

69. VicarioM, BlanchardC, StringerKF, et al.Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis. Gut2010;59:12. CrossRef

70. Molina‐InfanteJ, KatzkaDA, GisbertJP. Review article: proton pump inhibitor therapy for suspected eosinophilic oesophagitis. Aliment Pharmacol Ther2013;37:1157. CrossRef

71. RodrigoS, AbboudG, OhD, et al.High intraepithelial eosinophil counts in esophageal squamous epithelium are not specific for eosinophilic esophagitis in adults. Am J Gastroenterol2008;103:435. CrossRef

72. Molina‐InfanteJ, Ferrando‐LamanaL, RipollC, et al.Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol2011;9:110. CrossRef

73. KrarupAL, VilladsenGE, MejlgaardE, et al.Acid hypersensitivity in patients with eosinophilic oesophagitis. Scand J Gastroenterol2010;45:273. CrossRef

74. PetersonKA, ThomasKL, HildenK, et al.Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci2010;55:1313. CrossRef

75. KedikaRR, SouzaRF, SpechlerSJ. Potential anti‐inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci2009;54:2312. CrossRef

76. MurphyDW, YuanY, CastellDO. Does the intraesophageal pH probe accurately detect acid reflux? Simultaneous recording with two pH probes in humans. Dig Dis Sci1989;34:649. CrossRef

77. ChengE, ZhangX, HuoX, et al.Omeprazole blocks eotaxin‐3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut2013;62:824. CrossRef

78. RomanS, HiranoI, KwiatekMA, et al.Manometric features of eosinophilic esophagitis in esophageal pressure topography. Neurogastroenterol Motil2011;23:208. CrossRef

79. KwiatekMA, HiranoI, KahrilasPJ, et al.Mechanical properties of the esophagus in eosinophilic esophagitis. Gastroenterology2011;140:82. CrossRef

80. NicodèmeF, HiranoI, ChenJ, et al.Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol2013;11:1101. CrossRef

81. FranciosiJP, HommelKA, DeBrosseCW, et al.Quality of life in paediatric eosinophilic oesophagitis: what is important to patients?Child Care Health Dev2011;38:477. CrossRef

82. MarkowitzJE, SpergelJM, RuchelliE, et al.Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol2003;98:777. CrossRef

83. KagalwallaAF, SentongoTA, RitzS, et al.Effect of six‐food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol2006;4:1097. CrossRef

84. HendersonCJ, AboniaJP, KingEC, et al.Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol2012;129:1570. CrossRef

85. SpergelJM, Brown‐WhitehornTF, CianferoniA, et al.Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol2012;130:461. CrossRef

86. KonikoffMR, NoelRJ, BlanchardC, et al.A randomized double‐blind‐placebo controlled trial of fluticasone proprionate for pediatric eosinophilic esophagitis. Gastroenterology2006;131:1381. CrossRef

87. StraumannA, ConusS, DegenL, et al.Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology2010;139:1526–1537e1. CrossRef

88. DohilR, NewburyR, FoxL, et al.Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo‐controlled trial. Gastroenterology2010;139:418. CrossRef

89. AroraAS, PerraultJ, SmyrkTC. Topical corticosteroid treatment of dysphagia due to eosinophilic esophagitis in adults. Mayo Clin Proc2003;78:830. CrossRef

90. KlinnertMD. Psychological impact of eosinophilic esophagitis on children and families. Immunol Allergy Clin North Am2009;29:99. CrossRef

91. FaubionWAJr, PerraultJ, BurgartLJ, et al.Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr1998;27:90. CrossRef

92. AcevesSS, DohilR, NewburyRO, et al.Topical viscous budesonide suspension for treatment of eosinophilic esophagitis. J Allergy Clin Immunol2005;116:705. CrossRef

93. GroveA, AllamC, McFarlaneLC, et al.A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br J Clin Pharmacol1994;38:527. CrossRef

94. TeitelbaumJE, FoxVL, TwarogFJ, et al.Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. Gastroenterology2002;122:1216. CrossRef

95. SandersonCJ. Interleukin‐5, eosinophils, and disease. Blood1992;79:3101.

96. CollinsPD, MarleauS, Griffiths‐JohnsonDA, et al.Cooperation between interleukin‐5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med1995;182:1169. CrossRef

97. RothenbergME, PetersenJ, StevensRL, et al.IL‐5‐dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody‐dependent cytotoxicity. J Immunol1989;143:2311.

98. HamelmannE, CieslewiczG, SchwarzeJ, et al. Anti‐interleukin 5 but not anti‐IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med1999;160:934. CrossRef

99. StraumannA, ConusS, GrzonkaP, et al.Anti‐interleukin‐5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo‐controlled, double‐blind trial. Gut2010;59:21. CrossRef

100. SteinML, CollinsMH, VillanuevaJM, et al.Anti‐IL‐5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol2006;118:1312. CrossRef

101. ZimmermannN, HersheyGK, FosterPS, et al.Chemokines in asthma: cooperative interaction between chemokines and IL‐13. J Allergy Clin Immunol2003;111:227, quiz 243. CrossRef

102. ZhuZ, ZhengT, HomerRJ, et al.Acidic mammalian chitinase in asthmatic Th2 inflammation and IL‐13 pathway activation. Science2004;304:1678. CrossRef

103. PopeSM, FulkersonPC, BlanchardC, et al.Identification of a cooperative mechanism involving interleukin‐13 and eotaxin‐2 in experimental allergic lung inflammation. J Biol Chem2005;280:13952. CrossRef

104. BlanchardC, MinglerMK, VicarioM, et al.IL‐13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibilty with glucocorticoids. J Allergy Clin Immunol2007;120:204. CrossRef

105. CorrenJ, LemanskeRF, HananiaNA, et al.Lebrikizumab treatment in adults with asthma. N Engl J Med2011;365:1088. CrossRef

106. HersheyGK. IL‐13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol2003;111:677, quiz 691. CrossRef

107. UrbanJF, Noben‐TrauthN, DonaldsonDD, et al.IL‐13, IL‐4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis. Immunity1998;8:255. CrossRef

108. KweonM, YamamotoM, KajikiM, et al.Systemically derived large intestinal CD4+ Th2 cells play a central role in STAT‐6‐mediated allergic diarrhea. J Clin Invest2000;106:199. CrossRef

109. MatsukuraS, StellatoC, PlittJR, et al.Activation of eotaxin gene transcription by NF‐kappaB and STAT6 in human airway epithelial cells. J Immunol1999;163:6876.

110. ZimmermannN, HoganSP, MishraA, et al.Murine eotaxin‐2: a constitutive eosinophil chemokine induced by allergen challenge and IL‐4 overexpression. J Immunol2000;165:5839. CrossRef

111. MatsukuraS, StellatoC, GeorasSN, et al.Interleukin‐13 upregulates eotaxin expression in airway epithelial cells by a STAT6‐dependent mechanism. Am J Respir Cell Mol Biol2001;24:755. CrossRef

112. HoeckJ, WoisetschlagerM. STAT6 mediates eotaxin‐1 expression in IL‐4 or TNF‐alpha‐induced fibroblasts. J Immunol2001;166:4507. CrossRef

113. BlanchardC, DurualS, EstienneM, et al.Eotaxin‐3/CCL26 gene expression in intestinal epithelial cells is up‐regulated by interleukin‐4 and interleukin‐13 via the signal transducer and activator of transcription 6. Int J Biochem Cell Biol2005;37:2559. CrossRef

114. RothenbergME, MishraA, BrandtEB, et al.Gastrointestinal eosinophils. Immunol Rev2001;179:139. CrossRef

115. RothenbergME, HoganSP. The eosinophil. Annu Rev Immunol2006;24:147. CrossRef

116. BhardwajN, GhaffariG. Biomarkers for eosinophilic esophagitis: a review. Ann Allergy Asthma Immunol2012;109:155. CrossRef

117. PereiraS, ClarkT, DarbyY, et al.Effects of anti‐eotaxin monoclonal antibody CAT‐213 on allergen‐induced rhinitis. J Allergy Clin Immunol2003;111:S268. CrossRef

118. De LuccaGV, KimUT, VargoBJ, et al.Discovery of CC chemokine receptor‐3 (CCR3) antagonists with picomolar potency. J Med Chem2005;48:2194. CrossRef

119. SalibR, SalageanM, LauL, et al.The anti‐inflammatory response of anti‐eotaxin monoclonal antibody CAT‐213 on nasal allergen‐induced cell infiltration and activation. J Allergy Clin Immunol2003;111:S347. CrossRef

120. DentG, HadjicharalambousC, YoshikawaT, et al.Contribution of eotaxin‐1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am J Respir Crit Care Med2004;169:1110. CrossRef

121. FulkersonPC, RothenbergME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov2013;12:117. CrossRef

122. HiraiH, TanakaK, YoshieO, et al.Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven‐transmembrane receptor CRTH2. J Exp Med2001;193:255. CrossRef

123. NagataK, TanakaK, OgawaK, et al.Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol1999;162:1278.

124. SchuligoiR, SturmE, LuschnigP, et al.CRTH2 and D‐type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology2010;85:372. CrossRef

125. BarnesN, PavordI, ChuchalinA, et al.A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy2012;42:38. CrossRef

126. GreenRH, BrightlingCE, McKennaS, et al.Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet2002;360:1715. CrossRef

127. StraumannA. Treatment of eosinophilic esophagitis: diet, drugs, or dilation?Gastroenterology2012;142:1409. CrossRef

128. DeBrosseCW, FranciosiJP, KingEC, et al.Long‐term outcomes in pediatric‐onset esophageal eosinophilia. J Allergy Clin Immunol2011;128:132. CrossRef

129. DellonES, GibbsWB, FritchieKJ, et al.Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol2009;7:1305, quiz 1261. CrossRef

130. GonsalvesN, Policarpio‐NicolasM, ZhangQ, et al.Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc2006;64:313. CrossRef

131. PrasadGA, AlexanderJA, SchleckCD, et al.Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol2009;7:1055. CrossRef

132. SchoepferAM, GonsalvesN, BussmannC, et al.Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol2010;105:1062. CrossRef

133. LucendoAJ, De RezendeL. Endoscopic dilation in eosinophilic esophagitis: a treatment strategy associated with a high risk of perforation. Endoscopy2007;39:376, author reply 377. CrossRef

134. DellonES, GibbsWB, RubinasTC, et al.Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Gastrointest Endosc2010;71:706. CrossRef